NCT07002372 Effect of Video Viewing on Intravitreal Injection Experience
| NCT ID | NCT07002372 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Second Affiliated Hospital, School of Medicine, Zhejiang University |
| Condition | Age Related Macular Degeneration |
| Study Type | INTERVENTIONAL |
| Enrollment | 182 participants |
| Start Date | 2025-05-05 |
| Primary Completion | 2025-08-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 182 participants in total. It began in 2025-05-05 with a primary completion date of 2025-08-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Study Objective The goal of this clinical trial is to evaluate whether viewing a procedural video can improve the patient experience and reduce the incidence and severity of subconjunctival hemorrhage in individuals undergoing intravitreal anti-VEGF injections. Key Research Questions 1. Can viewing the procedural video prior to treatment reduce the rate and/or area of subconjunctival hemorrhage? 2. Can the video improve the patient experience, specifically by reducing anxiety levels and increasing satisfaction with the treatment process? Study Design Participants will be randomly assigned to either an intervention group, who will watch an educational video explaining the injection procedure, or a control group, who will not view the video. All participants will complete the State-Trait Anxiety Inventory-State (STAI-S) questionnaire both before and after treatment to assess changes in anxiety levels.
Eligibility Criteria
Inclusion Criteria: * Patients who are receiving their first intravitreal injection of anti-VEGF medication due to retinal diseases * Mentally competent, and able to communicate without barriers * Willing to voluntarily sign an informed consent form. Exclusion Criteria: * History of previous eye surgery * Best-corrected visual acuity in the better eye worse than 0.3 * The target eye is complicated with neovascular glaucoma.
Contact & Investigator
Xiaoyun Fang, MD., PhD
PRINCIPAL INVESTIGATOR
Second Affiliated Hospital, School of Medicine, Zhejiang University
Frequently Asked Questions
Who can join the NCT07002372 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Age Related Macular Degeneration. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07002372 currently recruiting?
Yes, NCT07002372 is actively recruiting participants. Contact the research team at xiaoyunfang@zju.edu.cn for enrollment information.
Where is the NCT07002372 trial being conducted?
This trial is being conducted at Hangzhou, China.
Who is sponsoring the NCT07002372 clinical trial?
NCT07002372 is sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University. The principal investigator is Xiaoyun Fang, MD., PhD at Second Affiliated Hospital, School of Medicine, Zhejiang University. The trial plans to enroll 182 participants.